Pharmacogenomics for Adverse Drug Reactions

Pharmacogenomics have long held the promise of using personalized information for drug selection to maximize efficacy and minimize adverse reactions. A new study evaluates the routine use of pharmacogenomic testing to improve safety in a wide range of medications. Join host, Geoff Wall, as he evaluates personalized medicine. The GameChanger Most studies using routine pharmacogenomic testing in clinical practice have not been significant. However, a new study found a 12 panel pharmacogenomic test did decrease the incidence of patient reported adverse effects compared to usual care. Several limitations still exist preventing widespread implementation. Show Segments 00:00 - Introductions 01:38 - Genomic Guided Therapy to Date 05:05 - Importance of Genomic Variations 08:37 - Looking at the Study 21:20 - The GameChanger: Swen et al Results 27:50 - Connecting to Practice: Current Barriers to Pharmacogenomic Testing 30:38- Closing Remarks Host Geoff Wall, PharmD, BCPS, FCCP, CGP Professor of Pharmacy Practice, Drake University Internal Medicine/Critical Care, UnityPoint Health References and Resources A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Clinical Pharmacogenomics Implementation Consortium. Redeem your CPE here CPE (Pharmacist) Get a membership & earn CE for GameChangers Podcast episodes (30 mins/episode) Pharmacists: Get a membership CE Information Learning Objectives Upon successful completion of this knowledge-based activity, participants should be able to: 1. Describe current barriers to routine use of pharmacogenomic testing 2. Discuss issues and results of the Swen et al study on pharmacogenomics 0.05 CEU/0.5 Hr UAN: 0107-0000-23-118-H01-P Initial release date: 03/20/2023 Expiration date: 03/20/2024 Additional CPE and CME details can be found here. Follow CEimpact on Social Media: LinkedIn Instagram